Formulation and Bioavailability Study on Some Anti-Asthmatic Drugs

Abstract

Diprophylline is a methylxanthines drug used in the treatment of bronchial asthma. The drug has proven therapeutic efficacy, tolerability and safety. The short plasma half-life, -2 hours, following oral dosing necessitates a three-time a day administration of the drug to maintain peak and trough concentrations within the therapeutic range. Patient compliance is known to be fairly poor with such frequent dosing regimen. Therefore, it was considered desirable to develop controlled-release preparations of diprophylline. Accordingly, the work in this thesis is divided into four chapters, namely, preparation and evaluation of diprophylline microcapsules, preparation and evaluation of sustained release diprophylline tablets and capsules, preparation and evaluation of sustained release diprophylline suppositories and finally bioavailability study of diprophylline from its selected formulations.